Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1988-11-21
pubmed:abstractText
Assessment of response of skeletal metastases to systemic therapy is currently dependent on radiological evidence of bone healing. We have performed a prospective study of additional response criteria in patients with progressive bone metastases from breast cancer. Changes in these potential markers of response were correlated with the radiological response and the time to treatment failure (TTF). Successful systemic therapy typically led to a transient increase in osteoblast activity ('flare'), a reduction in osteoclast activity and symptomatic improvement. After 1 month a greater than 10% rise in serum osteocalcin (BGP) and alkaline phosphatase bone isoenzyme (ALP-BI) and a greater than 10% fall in urinary calcium excretion were seen in 14/16 patients with radiographic evidence of bone healing (UICC partial responders). In comparison similar biochemical changes at 1 month were seen in only 4/20 patients with progressive disease (P less than 0.001). The predictive value and diagnostic efficiency (DE) of changes at 1 month in biochemical measurements and symptom score has been calculated. The combination of a greater than 10% rise in ALPBI and BGP and a greater than 10% fall in urinary calcium excretion had a DE of 89% for discriminating response from progression, 88% for response from non-response (progressing + no change patients), and 76% for TTF of greater than 6 months from TTF of less than 6 months. Serum calcium, tartrate resistant acid phosphatase (TRP), urinary hydroxyproline excretion and bone scan changes were unhelpful in discriminating between patient groups. Independent confirmation is needed, but our results suggest there are reliable alternatives to plain radiography in the early assessment of response of bone metastases to treatment.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-1149250, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-2938732, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-3560640, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-3798573, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-3814476, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-4179224, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-6235799, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-6692099, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-6692261, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-6831170, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-6861098, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-692598, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-6968755, http://linkedlifedata.com/resource/pubmed/commentcorrection/3262366-970368
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
205-10
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Biochemical prediction of response of bone metastases to treatment.
pubmed:affiliation
Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital, London, UK.
pubmed:publicationType
Journal Article